Ibrutinib + Venetoclax in Untreated WM

NCT04273139 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom Macroglobulinemia
MYD88 Gene Mutation

Interventions

DRUG: IBRUTINIB
DRUG: Venetoclax

Sponsor

Dana-Farber Cancer Institute

Collaborators

AbbVie
Pharmacyclics LLC.